<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Pfizer’s COVID-19 Candidate Has Moderate Side Effects
Image Overlay - Pfizer’s COVID-19 Candidate Has Moderate Side Effects

Pfizer’s COVID-19 Candidate Has Moderate Side Effects

Pfizer’s COVID-19 Candidate Has Moderate Side Effects

Pfizer has announced that participants in their phase III clinical trial had moderate side effects. More than 12,000 people have received a second round of the vaccine, with 29,000 enrolled in the trial. For phase III, Pfizer would like to increase enrollment to 44,000 including people as young as 16 and those with HIV and hepatitis C or B. Yourway’s primary and secondary packaging capabilities integrate seamlessly with our storage & distribution and premium courier services to enhance supply chain efficiency and facilitate shorter lead times compared to other clinical services and logistics companies.

Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Pharma Supply Chain & Logistics Innovation Programme EU

May 20-21, 2026
Basel, Switzerland

Clinical Trial Supply West Coast

September 22-23, 2026
Burlingame, CA

Media

Articles

Global Reach in Clinical Trials: Beyond Presence to True Execution

Open chat
Come chat with us!
Hello! How can I help you?